Dalteparin

Class Parenteral anticoagulant
Chemistry

Glycosaminoglycan

Routes of administration

IV ands subcut

Absorption

Minimal oral bioavailability (~ 1%)

Solubility

pKa -2.6, excellent solubility in water

Distribution

VOD=0.05L/kg, basically confined to the bloodstream.
Somewhat protein-bound, but less than unfractionated heparin (only the chains which are less than 6000 Da are protein-bound)

Metabolism

Small amount of dalteparin is metabolised into lower molecular weright framents, mainly in the liver

Elimination

70% of dalteparin is eliminated via the kidneys.
Monitoring is by measurement of anti-Xa activity

Time course of action

Half life is about 3-5 hours.

Target receptor

Antithrombin III

Mechanism of action

By binding to antithrombin III and causing the active site to undergo a conformational change, low molecular weight heparin increases its affinity for factor Xa (but not thrombin). The result is an increase in the activity of antithrombin on Factor Xa, which manifests in the form of the anticoagulant effect.

Clinical effects

Anticoagulation is the only clinically apparent effect; no significant side effects apart from the possibility of HITS (which is much smaller than with UFH)

Literature reference

Fragmin PI document

CICM details of understanding Not specifically listed in the CICM syllabus
Mentioned around Deranged Physiology
Related SAQs